The First Case Report of JAK2-BCR-PPP1R32 Fusion Genes Because of a Translocation (9;22;11) (p24;q11.2;q13) in a Patient With Myeloproliferative Neoplasm

Article Hematology

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm

Coen J. Lap et al.

Summary: Hematological malignancies with a BCR-JAK2 rearrangement have been sporadically described in literature, presenting significant clinical variability. Combining JAK2 and BCL2 inhibitors in treatment may offer a strategic approach for disease control, particularly in patients ineligible for stem cell transplantation. Further exploration of this combination therapy regimen in future studies is warranted due to its low toxicity profile.

CASE REPORTS IN HEMATOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

IIIG9 inhibition in adult ependymal cells changes adherens junctions structure and induces cellular detachment

Victor Baeza et al.

Summary: Ependymal cells with multiple apical cilia are important for brain function, and the protein IIIG9 plays a crucial role in maintaining their adherens junctions. Loss of ependymal cell polarity can lead to tumor formation, particularly in children, and understanding the function of IIIG9 may provide insights into potential therapies for conditions such as hydrocephalus or neoplastic transformation.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Hematology